Core Insights - Mabtech and Sai Life Sciences have formed a strategic collaboration to establish Sai's Boston laboratory as a co-marketed US execution and demonstration hub for the Mabtech EYRA™ platform [1][2] Group 1: Collaboration Details - The collaboration will jointly deliver advanced immunology assay services, including high-sensitivity multiplex cytokine and phenotyping workflows, utilizing the EYRA platform at Sai's Boston site [2] - This initiative aims to enhance access to next-generation immune profiling capabilities for biopharma and biotech companies involved in immuno-oncology, vaccines, inflammation, and cellular therapy [2][4] Group 2: Platform Features and Benefits - The EYRA platform features intuitive software, automation readiness, and the ability to simultaneously detect dozens of analytes in a single run with minimal hands-on time, addressing limitations of traditional systems [3] - The collaboration allows for the integration of advanced immune profiling into broader discovery and translational strategies, facilitating faster decision-making for discovery clients [4] Group 3: Key Elements of the Collaboration - Key elements include joint service delivery of EYRA-based immunology panels and custom assays, co-branded demonstrations and pilot programs at Sai Boston, shared thought leadership, and integrated business development engagement [7]